GENEVA—The recent success of treatment with immune checkpoint inhibitors suggests that immunotherapy could presently move center stage to play a leading role in fighting non-small cell lung cancer—the
GENEVA—The recent success of treatment with immune checkpoint inhibitors suggests that immunotherapy could presently move center stage to play a leading role in fighting non-small cell lung cancer—the European Lung Cancer Conference heard from Solange Peters, MD-PhD who leads the thoracic malignancies program in the Department of Oncology of the University of Lausanne. She discussed the new methods needed to harness these therapies and manage their toxicities with Oncology Times reporter Peter Goodwin.